AI · 17 November 2026 · 3 min read
Isomorphic Labs says it has raised $5 billion
Reuters reported on 17 November that Isomorphic Labs, the Alphabet-backed drug-design company, said it had raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. The company declined to give a valuation. Reuters said the round follows a $2.1 billion Series B about six months earlier. The company said the money is to move first drug candidates toward clinical trials.

Isomorphic Labs said on 17 November that it has raised $5 billion in a Series C, Reuters reported. The round was co-led by Greenoaks and Sequoia Capital. Reuters said Andreessen Horowitz and other new investors joined, Alphabet made a significant investment, and existing backers including Thrive, MGX and GV also took part. The company declined to share a valuation. Reuters said the round comes about six months after a $2.1 billion Series B led by Thrive Capital. Isomorphic was spun out of Google DeepMind in 2021.
Founder and chief executive Demis Hassabis said the round lets the company accelerate work on biology models, disease understanding, and its first therapeutic programmes toward clinical trials. Reuters said the company reported positive pre-clinical results in internal oncology and immunology programmes and with partners, and that this sets the stage for clinical entry. The report does not give a date for a first trial. Reuters said the company’s site lists Novartis, Eli Lilly and Johnson & Johnson as partners.
More in AI